HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

被引：0
|
作者：
Garrett, Joan T. [1 ]
Becker, Jennifer [1 ]
Estrada, Monica Valeria [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-212
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment of HER2-overexpressing breast cancer
    Baselga, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 40
  • [22] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
  • [23] Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer
    Zucchini, G.
    Bernardi, A.
    Martoni, A.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 264 - 265
  • [24] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
    K Mann
    M Kullberg
    Cancer Gene Therapy, 2016, 23 : 221 - 228
  • [25] Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
    Noor Al-Dasooqi
    Joanne M. Bowen
    Rachel J. Gibson
    Thomas Sullivan
    Jude Lees
    Dorothy M. Keefe
    Investigational New Drugs, 2009, 27 : 173 - 178
  • [26] Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
    Al-Dasooqi, Noor
    Bowen, Joanne M.
    Gibson, Rachel J.
    Sullivan, Thomas
    Lees, Jude
    Keefe, Dorothy M.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 173 - 178
  • [27] Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer
    Ewer, Michael S.
    O'Shaughnessy, Joyce A.
    CLINICAL BREAST CANCER, 2007, 7 (08) : 600 - 607
  • [28] Response to trastuzumab of HER2-overexpressing breast cancer patient-derived xenografts depends on the host mouse strain.
    Judde, Jean-Gabriel
    Deas, Olivier
    Lassalle, Myriam
    Boissay, Victorine
    Delaitre, Anais
    Nicolle, Delphine
    Cairo, Stefano
    Ginestier, Christophe
    Poupon, Marie-France
    Charafe-Jauffret, Emmanuelle
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [29] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    Burstein, HJ
    Kuter, I
    Campos, SM
    Gelman, RS
    Tribou, L
    Parker, LM
    Manola, J
    Younger, J
    Matulonis, U
    Bunnell, CA
    Partridge, AH
    Richardson, PG
    Clarke, K
    Shulman, LN
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
  • [30] Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
    Zhang, Dongwei
    Pal, Ashutosh
    Bornmann, William G.
    Yamasaki, Fumiyuki
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    Bartholomeusz, Chandra
    Ueno, Naoto T.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) : 1846 - 1850
12345